High-Throughput Screening for GPR119 Modulators Identifies a Novel Compound with Anti-Diabetic Efficacy in db/db Mice

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Zhang, Meng ^a   Feng, Yang ^a   Wang, Jia ^b   Zhao, Jianwei ^b   Li, Ting ^a   He, Min ^b   Yang, Dehua ^a   Nosjean, Olivier ^c   Boutin, Jean ^c   Renard, Pierre ^c   Wang, Ming Wei ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b Chinese National Compound Library   (China)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; AR 231453; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; MW 1219; SITAGLIPTIN; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG STRUCTURE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HIGH THROUGHPUT SCREENING; HORMONE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; MALE; MOUSE; NONHUMAN;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DRUG EVALUATION, PRECLINICAL; GLUCAGON-LIKE PEPTIDE 1; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED C57BL; OXADIAZOLES; PYRIMIDINES; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84878001008     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063861     Document Type: Article

References (23)

1. DeFronzo RA, Bonadonna RC, Ferrannini E, (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15: 318-368.
2. Taylor SI, Accili D, Imai Y, (1994) Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes 43: 735-740.
3. Stumvoll M, Goldstein BJ, van Haeften TW, (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333-1346.
4. Drucker DJ, Nauck MA, (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 854-865.
6. Lauffer L, Iakoubov R, Brubaker PL, (2008) GPR119: "double-dipping" for better glycemic control. Endocrinology 149: 2035-2037.
7. Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, et al. (2008) A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 149: 2038-2047.
8. Sakamoto Y, Inoue H, Kawakami S, Miyawaki K, Miyamoto T, et al. (2006) Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem Biophys Res Commun 351: 474-480.
9. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, et al. (2006) Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3: 167-175.
10. Chu ZL, Jones RM, He H, Carroll C, Gutierrez V, et al. (2007) A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148: 2601-2609.
11. Jones RM, Leonard JN, Buzard DJ, Lehmann J, (2009) GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat 19: 1339-1359.
12. May LT, Avlani VA, Sexton PM, Christopoulos A, (2004) Allosteric modulation of G protein-coupled receptors. Curr Pharm Des 10: 2003-2013.
13. Semple G, Fioravanti B, Pereira G, Calderon I, Uy J, et al. (2008) Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J Med Chem 51: 5172-5175.
14. Chu ZL, Carroll C, Chen R, Alfonso J, Gutierrez V, et al. (2010) N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol Endocrinol 24: 161-170.
15. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
16. Lan H, Lin HV, Wang CF, Wright MJ, Xu S, et al. (2012) Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. Br J Pharmacol 165: 2799-2807.
17. Brubaker PL, Schloos J, Drucker DJ, (1998) Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology 139: 4108-4114.
18. Williams C, (2004) cAMP detection methods in HTS: selecting the best from the rest. Nat Rev Drug Discov 3: 125-135.
19. Yoshida S, Tanaka H, Oshima H, Yamazaki T, Yonetoku Y, et al. (2010) AS1907417, a novel GPR119 agonist, as an insulinotropic and beta-cell preservative agent for the treatment of type 2 diabetes. Biochem Biophys Res Commun 400: 745-751.
20. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. nature 379: 69-72.
21. Young AA, Gedulin BR, Rink TJ, (1996) Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 45: 1-3.
22. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, et al. (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. nature 425: 90-93.
23. Meier JJ, Nauck MA, (2004) The potential role of glucagon-like peptide 1 in diabetes. Curr Opin Investig Drugs 5: 402-410.